Your Name:	Limei Chen
Manuscript Title:	_ The predictive value of tumor volume reduction ratio on three-dimensional endorectal
ultrasound for tumor	response to chemoradiotherapy for locally advanced rectal cancer
Manuscript number (	if known): ATM-22-2418

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	xNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Please summarize the above conflict of interest in the following box:			

None			

Date:	202	2/5/7		
Your I	Name:	Xiaoyin	Liu	
Manu	script Title:	The pre	dictive value of tumor vol	ume reduction ratio on three-dimensional endorectal
ultras	ound for tu	mor response	to chemoradiotherapy for	locally advanced rectal cancer
Manu	script numb	er (if known):	ATM-22-2418	
relate partie to tra relation. The formanu. The auto the medic	ed to the cores whose intensionship/activellowing questionscript only.  uthor's relate epidemiologication, even	ntent of your nerests may be and does not nerest, it estions apply to tionships/active of that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. it is preferable that you do to the author's relationship vities/interests should be go nsion, you should declare tion is not mentioned in t	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
			port for the work reported the past 36 months.	d in this manuscript without time limit. For all other items
			Name all entities with	Specifications/Comments
			whom you have this	(e.g., if payments were made to you or to your
			relationship or indicate	institution)
			none (add rows as	,
			needed)	
			Time frame: Since the initia	al planning of the work
1 /	All support fo	r the present	X None	
	manuscript (e	-		
		tudy materials,		
1 -	medical writir			
	processing ch	_		
		for this item.		
			Time frame-nee	t 26 months
2 /	Grants or con	tracts from	Time frame: pas	t 50 months
_   '			XNone	
	any entity (if i			
	n item #1 abo			
3 F	Royalties or li	censes	XNone	
	n 1:: *			
4 (	Consulting fee	es	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	xNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Please summarize the above conflict of interest in the following box:			

None			

Date:	2022/5/7		
Your I	Name:Wen	jing Zhang	
Manu	script Title: The	predictive value of tumor vol	ume reduction ratio on three-dimensional endorectal
ultras	ound for tumor respon	se to chemoradiotherapy for	locally advanced rectal cancer
Manu	script number (if know	n): ATM-22-2418	
relate partie to trai relatio The fo manu	ed to the content of your set whose interests may insparency and does no conship/activity/interest ollowing questions applaceript only.	or manuscript. "Related" mean be affected by the content of t necessarily indicate a bias. It, it is preferable that you do by to the author's relationship	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.  Is/activities/interests as they relate to the current of the cu
medic	cation, even if that med m #1 below, report all s	lication is not mentioned in th	all relationships with manufacturers of antihypertensive ne manuscript.  I in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed)	Internation of the country
		Time frame: Since the initia	planning of the work
	All support for the present	X_None	
	manuscript (e.g., funding,	1-	
1 -	provision of study material	is,	
	medical writing, article processing charges, etc.)		
-	No time limit for this item		
'	NO time initial for time item	•	
		<b>T</b> : <b>f</b>	2C manufacture and the second
2 7	Cuente en sestima I. C	Time frame: past	36 MONUS
_   '	Grants or contracts from	XNone	
	any entity (if not indicated		
	n item #1 above).	N N	
3 F	Royalties or licenses	XNone	
4 (	Consulting fees	XNone	
- I	consulting ices		<u> </u>

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	xNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Please summarize the above conflict of interest in the following box:			

None			

Date	e:	_2022/5/7				
Your	r Name:_	Si Qin				
Man	Manuscript Title: The predictive value of tumor volume reduction ratio on three-dimensional endorectal					
ultra	asound fo	or tumor response t	to chemoradiotherapy for	locally advanced rectal cancer		
Man	uscript r	number (if known):	ATM-22-2418			
relate to trelate The man The to the med	ted to the ies whose anspared tionship, following author's author's ne epiden lication, the m #1 because m #1	e content of your manager interests may be not	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive		
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial	Inlanning of the work		
1	A II	ant fan tha areas		planning of the work—		
1	manuscr provision medical processi	ort for the present ript (e.g., funding, n of study materials, writing, article ng charges, etc.)  limit for this item.	X_None			
			Time frame: past	36 months		
2	any enti	or contracts from ty (if not indicated #1 above).	XNone			
3	Royaltie	s or licenses	X_None			
4	Consulti	ng fees	XNone			

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	xNone	
	meetings and/or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Please summarize the above conflict of interest in the following box:			

None			

Date:	:2022/5/7		
Your	Name:Yin	ning Wang	
Manu	uscript Title: The	e predictive value of tumor vol	ume reduction ratio on three-dimensional endorectal
ultras	sound for tumor respo	nse to chemoradiotherapy for	locally advanced rectal cancer
Manu	uscript number (if know	wn): ATM-22-2418	
relate partie to tra relatie	ed to the content of your set whose interests man insparency and does not onship/activity/interests.	our manuscript. "Related" meany be affected by the content of not necessarily indicate a bias. est, it is preferable that you do	
	ollowing questions ap uscript only.	ply to the author's relationship	s/activities/interests as they relate to the <u>current</u>
to the medic	e epidemiology of hyp cation, even if that me m #1 below, report all	ertension, you should declare a	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.  In this manuscript without time limit. For all other items,
			C '5' :: /O
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)
		none (add rows as	institution
		needed)	
		Time frame: Since the initia	planning of the work
1 /	All support for the prese		
	manuscript (e.g., funding		
	provision of study mater		
1 -	medical writing, article	,	
	processing charges, etc.)		
	No time limit for this ite		
		Time frame: past	36 months
2 (	Grants or contracts from	-	
	any entity (if not indicate		
	in item #1 above).		
	Royalties or licenses	X None	
	, 2.0.00 0. 110011000		
4 (	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	V N		
6	Payment for expert	XNone		
	testimony			
7	Support for attending	X None		
,	meetings and/or travel	xNone		
	meetings and/or traver			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	X None		
11	Stock of Stock options			
12	Receipt of equipment,	X None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			

None			

		10.1.102 2.10 02.1	
Date	e:2022/5/7		
You	r Name: Jing Lin	1	
Mar	nuscript Title: The pre	edictive value of tumor volu	ime reduction ratio on three-dimensional endorectal
			ocally advanced rectal cancer
			·
	, , ,		
relat part to tr	ted to the content of your nies whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	elationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to th	•	nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive manuscript.
	em #1 below, report all sup time frame for disclosure is	•	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		

Time frame: past 36 months

X\_None

X\_None

X\_\_None

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

3

4

any entity (if not indicated

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	V N		
6	Payment for expert	XNone		
	testimony			
7	Support for attending	X None		
,	meetings and/or travel	xNone		
	meetings and/or traver			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	X None		
11	Stock of Stock options			
12	Receipt of equipment,	X None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			

None			

Date:_	2022/5/7		
Your N	Name:Qiu Che	en	
Manus	script Title: The pre	edictive value of tumor volu	ume reduction ratio on three-dimensional endorectal
ultraso	ound for tumor response	to chemoradiotherapy for	locally advanced rectal cancer
Manus	script number (if known):	ATM-22-2418	
related parties to tran relation The fo manus	d to the content of your r s whose interests may be nsparency and does not n onship/activity/interest, i ollowing questions apply t script only.	manuscript. "Related" mean affected by the content of ecessarily indicate a bias. I t is preferable that you do to the author's relationship	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.  Is/activities/interests as they relate to the current of the cu
medic In iten	ation, even if that medica	ntion is not mentioned in the port for the work reported	all relationships with manufacturers of antihypertensive ne manuscript.  I in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	planning of the work
1 A	All support for the present	X None	
	nanuscript (e.g., funding,		
	provision of study materials,		
n	nedical writing, article		
р	processing charges, etc.)		
N	No time limit for this item.		
		Time frame: past	36 months
2 G	Grants or contracts from	XNone	
a	ny entity (if not indicated		
	n item #1 above).		
3 R	Royalties or licenses	XNone	
4 C	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	V N		
6	Payment for expert	XNone		
	testimony			
7	Support for attending	X None		
,	meetings and/or travel	xNone		
	meetings and/or traver			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid Stock or stock options	X None		
11	Stock of Stock options			
12	Receipt of equipment,	X None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			

None			

		ICMJE DISCI	OSURE FORM				
Date	e:2022/5/7						
Your	ate:2022/5/7 our Name: Guangjian Liu						
Man	nuscript Title: The pre	dictive value of tumor vo	lume reduction ratio on three-dimensional endorectal				
ultra	asound for tumor response	to chemoradiotherapy for	locally advanced rectal cancer				
Man	nuscript number (if known):	ATM-22-2418					
relat part to tr	n the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are elated to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment o transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a elationship/activity/interest, it is preferable that you do so.						
	following questions apply to nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>				
to th	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.						
	n item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, he time frame for disclosure is the past 36 months.						
		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	_	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone					
	lectures, presentations,						
	speakers bureaus,						
	manuscript writing or						
	educational events	V N					
6	Payment for expert	XNone					
	testimony						
7	Support for attending	X None					
,	meetings and/or travel						
	meetings and/or traver						
8	Patents planned, issued or	XNone					
	pending						
9	Participation on a Data	XNone					
	Safety Monitoring Board or						
_	Advisory Board						
10	Leadership or fiduciary role	X_None					
	in other board, society,		_				
	committee or advocacy group, paid or unpaid						
11	Stock or stock options	X None					
11	Stock of Stock options						
12	Receipt of equipment,	X None					
	materials, drugs, medical						
	writing, gifts or other						
	services						
13	Other financial or non-	XNone					
	financial interests						
Please summarize the above conflict of interest in the following box:							

None			